Rhizen Pharmaceuticals SA   Report issue

For profit Phase 1 Phase 2
Founded: La Chaux-de-Fonds Switzerland (2008)

Organization Overview

First Clinical Trial
2013
NCT02017613
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Rhizen Pharmaceuticals SA

Active Ingredients

Drugs in Phase 2 Trials (5)

pembrolizumab (keytruda) (1 trial)

romidepsin (istodax) (1 trial)

rp3128 (1 trial)

rp7214 (3 trials)

tenalisib (7 trials)

Drugs in Phase 1 Trials (3)

rp12146 (1 trial)

rp4010 (1 trial)

rp6530 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hodgkin Disease (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 1)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 16
  • # of Trial APIs: 8